Logo Logo
Help
Contact
Switch Language to German
Praetner, Marc; Zuchtriegel, Gabriele; Holzer, Martin; Uhl, Bernd; Schaubaecher, Johanna; Mittmann, Laura; Fabritius, Matthias; Fürst, Robert; Zahler, Stefan; Funken, Dominik; Lerchenberger, Maximilian; Khandoga, Andrej; Kanse, Sandip; Lauber, Kirsten; Krombach, Fritz; Reichel, Christoph A. (2018): Plasminogen Activator Inhibitor-1 Promotes Neutrophil Infiltration and Tissue Injury on Ischemia–Reperfusion. In: Arteriosclerosis Thrombosis and Vascular Biology, Vol. 38, No. 4: pp. 829-842
Full text not available from 'Open Access LMU'.

Abstract

Objective Ischemia-reperfusion (I/R) injury significantly contributes to organ dysfunction and failure after myocardial infarction, stroke, and transplantation. In addition to its established role in the fibrinolytic system, plasminogen activator inhibitor-1 has recently been implicated in the pathogenesis of I/R injury. The underlying mechanisms remain largely obscure. Approach and Results Using different in vivo microscopy techniques as well as ex vivo analyses and in vitro assays, we identified that plasminogen activator inhibitor-1 rapidly accumulates on microvascular endothelial cells on I/R enabling this protease inhibitor to exhibit previously unrecognized functional properties by inducing an increase in the affinity of 2 integrins in intravascularly rolling neutrophils. These events are mediated through low-density lipoprotein receptor-related protein-1 and mitogen-activated protein kinase-dependent signaling pathways that initiate intravascular adherence of these immune cells to the microvascular endothelium. Subsequent to this process, extravasating neutrophils disrupt endothelial junctions and promote the postischemic microvascular leakage. Conversely, deficiency of plasminogen activator inhibitor-1 effectively reversed leukocyte infiltration, microvascular dysfunction, and tissue injury on experimental I/R without exhibiting side effects on microvascular hemostasis. Conclusions Our experimental data provide novel insights into the nonfibrinolytic properties of the fibrinolytic system and emphasize plasminogen activator inhibitor-1 as a promising target for the prevention and treatment of I/R injury.